Tamoxifen News and Research

RSS

Tamoxifen is a drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen is a type of antiestrogen. Also called tamoxifen citrate.

Genetic variations can identify women who are likely to benefit from breast cancer prevention drug

Scientists found genetic variations that could be used to identify women who are most likely to benefit from a certain type of breast cancer prevention drug—and who should avoid it.

3 Jul 2013

Prosigna Breast Cancer Prognostic Gene Signature Assay study published in JCO

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that the TransATAC clinical validation study for its Prosigna Breast Cancer Prognostic Gene Signature Assay, which is based on the PAM50 gene signature, was published in the Journal of Clinical Oncology.

From NanoString Technologies 2 Jul 2013

Biomarker indicates which women are at risk for breast cancer recurrence after tamoxifen

A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor (ER)-positive breast cancer should receive a second estrogen-blocking medication after completing tamoxifen treatment.

30 Jun 2013

Brisdelle receives FDA approval to treat hot flashes associated with menopause

The U.S. Food and Drug Administration today approved Brisdelle (paroxetine) to treat moderate to severe hot flashes (vasomotor symptoms) associated with menopause. Brisdelle, which contains the selective serotonin reuptake inhibitor paroxetine mesylate, is currently the only non-hormonal treatment for hot flashes approved by the FDA.

29 Jun 2013

Diet, lifestyle and environment attribute to the cause of majority of cancer cases

Diet, lifestyle and the environment are all factors attributed to the cause of the majority of cancer cases and it has been estimated that up to half of all cancers may be preventable according to research by a University of Leicester scientist.

19 Jun 2013

Bazedoxifene used for treating osteoporosis stops growth of breast cancer cells

A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a Duke Cancer Institute study.

17 Jun 2013

Gene variants may predict which women are most likely to benefit from breast cancer therapy

In women at high risk for breast cancer, a long-term drug treatment can cut the risk of developing the disease in half. Researchers supported by the National Institutes of Health have now identified two gene variants that may predict which women are most likely to benefit from this therapy—and which should avoid it.

14 Jun 2013

Genetic variations may help predict breast cancer risk in women who receive preventive therapy

Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective estrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found. The study is published in the journal Cancer Discovery.

14 Jun 2013

Findings provide basis for reinvigoration of research efforts in breast cancer prevention

Genetic variations, known as single nucleotide polymorphisms, in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.

14 Jun 2013

NanoString's Prosigna Breast Cancer Assay can help identify node-positive early-stage breast cancer

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced new results from the combined data analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Arimidex, Tamoxifen, Alone or in Combination studies.

From NanoString Technologies 3 Jun 2013

NanoString Technologies to present clinical study of Prosigna Breast Cancer Assay at ASCO 2013

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced that a clinical study of the Prosigna Breast Cancer Assay will be presented during the Breast Cancer Oral Abstract Session at the 2013 Annual American Society of Clinical Oncology Meeting on Sunday, June 2.

From NanoString Technologies 1 Jun 2013

UIC's Center for Clinical and Translational Science selects six research projects for new pilot grants

The University of Illinois at Chicago's Center for Clinical and Translational Science has selected six research projects to receive pilot grants in 2013.

15 May 2013

New findings to benefit women with oestrogen-receptor positive breast cancer

A new analysis has provided a comprehensive comparison of scores designed to predict which women with oestrogen-receptor positive breast cancer are at high risk of recurrence beyond five years after diagnosis, and may benefit from prolonged endocrine treatment.

3 May 2013

Prosigna Breast Cancer Prognostic Gene Signature Assay predicts ROR in women with early-stage breast cancer

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced results from two studies that are featured in oral presentations this week at IMPAKT Breast Cancer Conference.

2 May 2013

Research shows coffee may decrease risk of cancer recurring in breast cancer patients

Drinking coffee could decrease the risk of breast cancer recurring in patients taking the widely used drug Tamoxifen, a study at Lund University in Sweden has found. Patients who took the pill, along with two or more cups of coffee daily, reported less than half the rate of cancer recurrence, compared with their non-coffee drinking, Tamoxifen-taking counterparts.

25 Apr 2013

Promising development for women with triple-negative breast cancer

Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center team has shown how to exploit tamoxifen's secondary activities so that it might work on more aggressive breast cancer.

24 Apr 2013

Long winter months impact tamoxifen treatment for breast cancer

For women diagnosed with a form of breast cancer known as estrogen receptor positive (ER+) breast cancer, tamoxifen is an essential drug used in the treatment and prevention of recurring breast cancer.

19 Apr 2013

Androgen receptors found to be a potential target in breast cancer

Estrogen and progesterone receptors, and the gene HER2 - these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: androgen receptors.

11 Apr 2013

Research shows omega-3 fatty acids stop proliferation of triple-negative breast cancer cells

Researchers from Fox Chase Cancer Center have found that omega-3 fatty acids and their metabolite products slow or stop the proliferation, or growth in the number of cells, of triple-negative breast cancer cells more effectively than cells from luminal types of the disease.

10 Apr 2013

New study shows some women don't stick to recommended treatment for breast cancer

One-quarter of women who should take hormone-blocking therapies as part of their breast cancer treatment either do not start or do not complete the five-year course, according to a new study led by University of Michigan Comprehensive Cancer Center researchers.

10 Apr 2013

Tamoxifen News and Research

Further Reading

Genetic variations can identify women who are likely to benefit from breast cancer prevention drug

Prosigna Breast Cancer Prognostic Gene Signature Assay study published in JCO

Biomarker indicates which women are at risk for breast cancer recurrence after tamoxifen

Brisdelle receives FDA approval to treat hot flashes associated with menopause

Diet, lifestyle and environment attribute to the cause of majority of cancer cases

Bazedoxifene used for treating osteoporosis stops growth of breast cancer cells

Gene variants may predict which women are most likely to benefit from breast cancer therapy

Genetic variations may help predict breast cancer risk in women who receive preventive therapy

Findings provide basis for reinvigoration of research efforts in breast cancer prevention

NanoString's Prosigna Breast Cancer Assay can help identify node-positive early-stage breast cancer

NanoString Technologies to present clinical study of Prosigna Breast Cancer Assay at ASCO 2013

UIC's Center for Clinical and Translational Science selects six research projects for new pilot grants

New findings to benefit women with oestrogen-receptor positive breast cancer

Prosigna Breast Cancer Prognostic Gene Signature Assay predicts ROR in women with early-stage breast cancer

Research shows coffee may decrease risk of cancer recurring in breast cancer patients

Promising development for women with triple-negative breast cancer

Long winter months impact tamoxifen treatment for breast cancer

Androgen receptors found to be a potential target in breast cancer

Research shows omega-3 fatty acids stop proliferation of triple-negative breast cancer cells

New study shows some women don't stick to recommended treatment for breast cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News